As a R&D-driven enterprise with no production assets, QuNaMai focuses 100% on high-barrier medical technology fields. Its core business directions include:
- Tissue Engineering (allogeneic natural killer cells, regenerative scaffolds)
- Medical Aesthetic Technology (R&D of microsphere injectables)
- High-end Preparations (medical-grade skincare products / functional foods)
- Emergency Medical Shelters (modular rapid deployment design)
- Cooperation Logic: Leverage investors' resources to accelerate global market penetration.
- Core Advantage: Increase market access speed by 30%-40% (e.g., obtaining FDA/CE certifications through partners' networks).
- Target Planning:
- Mid-term: Capture 15%-20% of the regional market share in the regenerative medicine / medical aesthetics sectors.
- Long-term: Expand into emerging markets, achieving an output value of 2.2-2.7 billion yuan and an annual profit growth rate of 25%.
- Core Commitment: QuNaMai assumes no production risks and only takes responsibility for ensuring technological stability and innovation.
- Mandatory Requirement: Possess compliance certification capabilities in target markets (e.g., FDA, CE).
- Key Cooperation Targets:
- Global medical technology investors seeking high-profit portfolios.
- Cosmetics / health food brands in need of breakthrough formulas.
- Medical OEM enterprises looking to upgrade their technology pipelines.
- View Technology Certifications: Visit the official website (www.tl-wc.com), which includes product demonstrations, market analyses, and technical specifications.
- Direct Contact Methods:
- Email: qunamai@163.com
- Whatsapp: +86 15355436798
- Service Commitment: Assign an exclusive technical / market consultant within 24 hours and provide customized cooperation plans.
✅ Leadership in Niche Segments: Own 4 patent-protected technology systems in high-growth tracks.
✅ Low-Risk Scaling: The asset-light model ensures fast return on investment (ROI) with no capital expenditure (CAPEX) burden.
✅ Global Compliance Bridge: Shorten regulatory approval processes through partner synergy.